JP4283474B2 - ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療 - Google Patents

ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療 Download PDF

Info

Publication number
JP4283474B2
JP4283474B2 JP2001505952A JP2001505952A JP4283474B2 JP 4283474 B2 JP4283474 B2 JP 4283474B2 JP 2001505952 A JP2001505952 A JP 2001505952A JP 2001505952 A JP2001505952 A JP 2001505952A JP 4283474 B2 JP4283474 B2 JP 4283474B2
Authority
JP
Japan
Prior art keywords
antibody
erbb2
cells
antibodies
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001505952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003503366A (ja
JP2003503366A5 (enExample
Inventor
アダムス，カメリア，ダブリュ．
プレスタ，レオナード，ジー．
スリューコースキー，マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22495168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4283474(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2003503366A publication Critical patent/JP2003503366A/ja
Publication of JP2003503366A5 publication Critical patent/JP2003503366A5/ja
Application granted granted Critical
Publication of JP4283474B2 publication Critical patent/JP4283474B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Packages (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2001505952A 1999-06-25 2000-06-23 ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療 Expired - Lifetime JP4283474B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60/141,316 1999-05-26
US14131699P 1999-06-25 1999-06-25
PCT/US2000/017366 WO2001000245A2 (en) 1999-06-25 2000-06-23 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008333670A Division JP2009142280A (ja) 1999-06-25 2008-12-26 ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療

Publications (3)

Publication Number Publication Date
JP2003503366A JP2003503366A (ja) 2003-01-28
JP2003503366A5 JP2003503366A5 (enExample) 2008-06-05
JP4283474B2 true JP4283474B2 (ja) 2009-06-24

Family

ID=22495168

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001505952A Expired - Lifetime JP4283474B2 (ja) 1999-06-25 2000-06-23 ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療
JP2008333670A Withdrawn JP2009142280A (ja) 1999-06-25 2008-12-26 ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008333670A Withdrawn JP2009142280A (ja) 1999-06-25 2008-12-26 ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療

Country Status (32)

Country Link
EP (2) EP2112167A3 (enExample)
JP (2) JP4283474B2 (enExample)
KR (2) KR100797308B1 (enExample)
CN (4) CN101121021B (enExample)
AR (1) AR024464A1 (enExample)
AT (2) ATE437655T1 (enExample)
AU (2) AU784045B2 (enExample)
BE (1) BE2013C020I2 (enExample)
BR (2) BR122014028365B8 (enExample)
CA (2) CA2376596C (enExample)
CH (1) CH694589A5 (enExample)
CY (2) CY1109525T1 (enExample)
CZ (1) CZ299702B6 (enExample)
DE (2) DE60042648D1 (enExample)
DK (1) DK1189641T5 (enExample)
ES (1) ES2329437T3 (enExample)
FR (1) FR13C0016I2 (enExample)
GB (1) GB2368796B (enExample)
GE (1) GEP20104998B (enExample)
HU (1) HU226742B1 (enExample)
IL (3) IL146954A0 (enExample)
LU (1) LU92164I2 (enExample)
MX (1) MXPA01013458A (enExample)
NO (3) NO328377B1 (enExample)
NZ (2) NZ516830A (enExample)
PL (2) PL204629B1 (enExample)
PT (1) PT1189641E (enExample)
RU (2) RU2270029C2 (enExample)
SI (3) SI2283866T1 (enExample)
TR (1) TR200103756T2 (enExample)
WO (1) WO2001000245A2 (enExample)
ZA (2) ZA200109786B (enExample)

Families Citing this family (238)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
EP1191944A2 (en) * 1999-06-25 2002-04-03 Genentech, Inc. METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
EP2112167A3 (en) * 1999-06-25 2010-12-22 Genentech, Inc. Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
MXPA02002037A (es) * 1999-08-27 2002-10-31 Genentech Inc Dosificaciones para el tratamiento con anticuerpos anti-erb2.
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CN102698265A (zh) 2000-05-19 2012-10-03 杰南技术公司 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验
EP1228766A1 (en) * 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
GB2397018B (en) * 2001-10-26 2006-05-31 Altarex Medical Corp Combination therapy for treating disease
AU2003262190A1 (en) * 2002-04-11 2003-10-27 Amgen Inc. Her-2 receptor tyrosine kinase molecules and uses thereof
ITTO20020340A1 (it) * 2002-04-19 2003-10-20 Biother Di Contardi Gabriella Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
WO2003101401A2 (en) 2002-06-03 2003-12-11 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
NO340576B1 (no) * 2002-07-11 2017-05-15 Hoffmann La Roche Rekombinant, humanisert antistoff 2C4 (rhuMab 2C4) for anvendelse sammen med et andre, forskjellig vekstinhiberende anti-ErbB2-antistoff i en fremgangsmåte for behandling av kreft i en pasient og anvendelse derav for fremstilling av et medikament
PL214010B1 (pl) * 2002-07-15 2013-06-28 Genentech Inc Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala
TR200500108T2 (tr) 2002-07-18 2005-04-21 Helix Biopharma Corp. Kanser Hücresi Gelişiminin İnhibe Edilmesinde Üreaz Kullanımı
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US7264800B2 (en) 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
CA2494310A1 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CN101972478B (zh) * 2002-10-08 2012-10-31 免疫医疗公司 抗体治疗
WO2004054622A1 (en) * 2002-12-13 2004-07-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
EP1613736A4 (en) * 2003-03-11 2007-04-11 Dana Farber Cancer Inst Inc INHIBITION OF VIRUS PATHOGENESIS
JP2007525458A (ja) * 2003-04-23 2007-09-06 メダレックス インコーポレイテッド インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP3095793B1 (en) 2003-07-28 2020-03-25 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
US20070104714A1 (en) * 2003-08-29 2007-05-10 Cedars-Sinai Medical Center Composition and method for the treatment of cancer and other physiologic conditins based on modulation of the ppar-gamma pathway and her-kinase axis
AU2004274487B2 (en) * 2003-09-18 2011-09-01 Macrogenics West, Inc. KID3 and KID3 antibodies that bind thereto
US20080267865A1 (en) * 2003-11-28 2008-10-30 Biotech Igg Ab Targeting of Erb Antigens
RU2402568C2 (ru) * 2004-02-06 2010-10-27 МорфоСис АГ Человеческие анти-cd38-антитела и их применение
RU2273475C2 (ru) * 2004-04-06 2006-04-10 Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ) Способ лечения диссеминированного колоректального рака
KR101200133B1 (ko) 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
RU2361880C2 (ru) 2004-07-22 2009-07-20 Дженентек, Инк. Композиция антител к her2
HUE030079T2 (en) 2004-09-23 2017-04-28 Genentech Inc Cysteine-manipulated antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005314127A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a HER inhibitor
KR20190016616A (ko) 2005-01-21 2019-02-18 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
MY152164A (en) 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
EP1871163A2 (en) 2005-06-06 2008-01-02 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
EP1922410A2 (en) 2005-08-15 2008-05-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
KR101164820B1 (ko) 2005-09-22 2012-07-12 삼성전자주식회사 디스플레이장치
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
JP2009516514A (ja) 2005-11-21 2009-04-23 ジェネンテック・インコーポレーテッド 新規遺伝子破壊、それらに関する組成物および方法
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JP2009527227A (ja) 2006-02-17 2009-07-30 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
SG172656A1 (en) 2006-05-30 2011-07-28 Genentech Inc Antibodies and immunoconjugates and uses therefor
JP2009539836A (ja) * 2006-06-05 2009-11-19 ジェネンテック・インコーポレーテッド ＥＧＦまたはＴＧＦ−αのレベルの上昇が生じている癌患者の生存の延長
MY150756A (en) 2006-08-21 2014-02-28 Hoffmann La Roche Tumor theraphy with an anti-vegf antibody
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
NZ576855A (en) * 2006-10-12 2012-08-31 Forerunner Pharma Res Co Ltd Diagnosis and treatment of cancer using anti-ereg antibody
NZ576132A (en) 2006-10-27 2012-04-27 Genentech Inc Antibodies and immunoconjugates and uses therefor
AU2008223069B2 (en) 2007-03-02 2012-12-13 F. Hoffmann-La Roche Ag Predicting response to a HER dimerisation inhibitor based on low HER3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
SI2171090T1 (sl) 2007-06-08 2013-07-31 Genentech, Inc. Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
US20100254996A1 (en) * 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
CA2692819A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
KR101486615B1 (ko) 2007-07-16 2015-01-28 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
HUE027668T2 (en) 2007-10-30 2016-11-28 Genentech Inc Antibody purification by cation exchange chromatography
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2009080694A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
AU2008346734A1 (en) 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
EP4427805A3 (en) 2008-01-31 2024-12-18 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
KR20160066557A (ko) * 2008-03-14 2016-06-10 제넨테크, 인크. 약물 저항성과 관련된 유전적 변이
BRPI0906181A2 (pt) * 2008-03-18 2015-06-30 Genentech Inc "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
JP2011521009A (ja) 2008-05-23 2011-07-21 シワ コーポレイション 再生を促進させる方法、組成物及び装置
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP5705115B2 (ja) 2008-09-10 2015-04-22 ジェネンテック， インコーポレイテッド 蛋白質の酸化的分解の予防のための組成物および方法
TR201910848T4 (tr) 2009-02-13 2019-08-21 Immunomedics Inc İntraselüler olarak ayrilabi̇len bi̇r bağa sahi̇p i̇mmunokonjugatlar
TW201544123A (zh) 2009-03-20 2015-12-01 Genentech Inc 抗-ｈｅｒ抗體
CN102471380B (zh) 2009-04-01 2015-01-14 霍夫曼-拉罗奇有限公司 抗FcRH5抗体和免疫偶联物及使用方法
CA2757426A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-2/anti-c-met antibodies
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
MX2012001742A (es) 2009-08-11 2012-03-21 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
AU2010284446A1 (en) * 2009-08-15 2012-03-08 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
BR112012004697B8 (pt) 2009-09-01 2021-05-25 Genentech Inc método para purificar um polipeptídeo compreendendo uma região ch2/ch3
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011044368A1 (en) 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
WO2011059762A1 (en) * 2009-10-28 2011-05-19 Abbott Biotherapeutics Corp. Anti-egfr antibodies and their uses
KR101968766B1 (ko) 2009-11-05 2019-04-12 제넨테크, 인크. 이종 폴리펩티드의 분비를 위한 방법 및 조성물
TWI630916B (zh) 2009-11-13 2018-08-01 第一三共歐洲公司 供治療或預防人表皮生長因子受體－３（ｈｅｒ－３）相關疾病之藥料和方法
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
JP5742714B2 (ja) * 2010-02-04 2015-07-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
MY160556A (en) 2010-02-18 2017-03-15 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
HRP20190751T1 (hr) 2010-03-22 2019-06-14 F. Hoffmann - La Roche Ag Pripravci i postupci korisni za stabilizaciju formulacija koje sadrže proteine
CN102958538A (zh) 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 用于降低含有蛋白质的制剂的粘度的组合物和方法
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
AU2011257121A1 (en) 2010-05-27 2013-01-10 Genmab A/S Monoclonal antibodies against HER2
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
SI2576580T1 (sl) 2010-05-28 2016-12-30 F. Hoffmann-La Roche Ag Znižanje nivoja laktata in zvišanje produkcije polipeptida z znižanjem ravni izražanja laktat-dehidrogenaze in piruvat-dehidrogenaza-kinaze
MX336109B (es) 2010-06-03 2016-01-08 Genentech Inc Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
CN107335062B (zh) 2010-06-08 2021-09-24 基因泰克公司 半胱氨酸改造的抗体和偶联物
MX339666B (es) 2010-06-24 2016-06-03 Genentech Inc * Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
CA2820095C (en) 2010-12-21 2019-02-26 F. Hoffmann-La Roche Ag Isoform enriched antibody preparation and method for obtaining it
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012085113A1 (en) 2010-12-23 2012-06-28 Roche Diagnostics Gmbh Binding agent
US8987257B2 (en) 2011-01-31 2015-03-24 Novartis Ag Heterocyclic derivatives
US9133270B2 (en) 2011-03-08 2015-09-15 The Trustees Of The University Of Pennsylvania Antibody-like proteins for therapeutic and diagnostic use
US20140170149A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
EP2744824A1 (en) 2011-08-17 2014-06-25 F.Hoffmann-La Roche Ag Neuregulin antibodies and uses thereof
UA123092C2 (uk) 2011-10-14 2021-02-17 Дженентек, Інк. Спосіб неоад'ювантного лікування her2-позитивного раку молочної залози на ранній стадії у пацієнта
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
PL2771342T3 (pl) 2011-10-28 2016-11-30 Nowe pochodne puryny i ich zastosowanie w leczeniu chorób
US9220775B2 (en) 2011-11-23 2015-12-29 Medimmune Llc Binding molecules specific for HER3 and uses thereof
BR112014012979A2 (pt) 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
BR112014015101A8 (pt) 2011-12-22 2021-06-08 Genentech Inc métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
EP2809805A1 (en) 2012-01-31 2014-12-10 SmithKline Beecham (Cork) Limited Method of treating cancer
EP2638916A1 (en) 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
MX2014011500A (es) 2012-03-27 2014-12-05 Genentech Inc Diagnosticos y tratamientos relacionados a inhibidores her3.
KR102171431B1 (ko) 2012-04-20 2020-10-30 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
KR101505157B1 (ko) 2012-05-08 2015-03-24 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
EP2849756A1 (en) 2012-05-16 2015-03-25 Novartis AG Dosage regimen for a pi-3 kinase inhibitor
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
US20150329524A1 (en) 2013-01-10 2015-11-19 Glaxosmithkline Intellectual Property (No.2) Limited Fatty acid synthase inhibitors
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
CN105451767B (zh) 2013-03-15 2019-10-18 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
CN104628846B (zh) 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
CA2919359C (en) 2013-11-19 2019-01-15 Remegen, Ltd. Anti-her2 antibody and conjugate thereof
SI3074424T1 (sl) 2013-11-27 2025-06-30 Zymeworks Bc Inc. Bispecifični konstrukti, ki vežejo antigen, ki ciljajo her2
HUE057092T2 (hu) 2013-12-06 2022-04-28 Novartis Ag Alfa-izoformára szelektív foszfatidilinozitol-3-kináz-inhibitor adagolási rendje
LT3101032T (lt) 2014-01-31 2019-03-25 Daiichi Sankyo Company, Limited Anti-her2 antikūno ir vaisto konjugatas
WO2015128837A1 (en) 2014-02-26 2015-09-03 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
WO2015139046A1 (en) 2014-03-14 2015-09-17 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
MX2016012830A (es) 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
AU2015314826A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2961603C (en) 2014-09-19 2021-07-13 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
EP4512428A3 (en) 2014-11-27 2025-05-21 Zymeworks BC Inc. Methods of using bispecific antigen-binding constructs targeting her2
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
KR101515535B1 (ko) 2015-01-28 2015-05-06 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US11028182B2 (en) 2015-05-13 2021-06-08 Zymeworks Inc. Antigen-binding constructs targeting HER2
EP3331919A1 (en) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
RU2766209C2 (ru) * 2015-10-13 2022-02-09 Сива Корпорейшн Антитела к age и способы их применения
AU2016347881A1 (en) 2015-11-02 2018-05-10 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
BR112018011228A2 (pt) 2015-12-01 2019-01-15 Glaxosmithkline Intellectual Property Development Limited tratamentos de combinação e seus usos e métodos
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
CN105646704B (zh) * 2015-12-28 2019-11-15 广西医科大学 抗p185erbB2人鼠嵌合抗体ChAb26、乳腺特异性表达载体、转基因FVB小鼠及其制备方法
JP6722293B2 (ja) 2016-02-19 2020-07-15 シワ コーポレーション 終末糖化産物（ａｇｅ）に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物
CN109310754A (zh) * 2016-03-15 2019-02-05 梅里麦克制药股份有限公司 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
US11958900B2 (en) 2016-04-15 2024-04-16 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
SG11201810032PA (en) * 2016-05-12 2018-12-28 Agency Science Tech & Res Anti-erbb-2 antibodies and uses thereof
US11213585B2 (en) 2016-06-23 2022-01-04 Siwa Corporation Vaccines for use in treating various diseases and disorders
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
EP3524267A4 (en) 2016-10-07 2020-06-10 Daiichi Sankyo Company, Limited THERAPY FOR DRUG-RESISTANT CANCER BY ADMINISTERING ANTI-HER2 ANTIBODIES / DRUG CONJUGATE
CN110049779A (zh) 2016-12-12 2019-07-23 第一三共株式会社 抗体-药物缀合物和免疫检查点抑制剂的组合
US11390685B2 (en) 2017-01-06 2022-07-19 Biosion, Inc. ErbB2 antibodies and uses therefore
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
WO2018160138A1 (en) 2017-03-02 2018-09-07 Aslan Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
PT3589661T (pt) 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2
MA49279A (fr) 2017-03-22 2020-02-05 Hoffmann La Roche Compositions d'anticorps optimisées pour le traitement de troubles oculaires
JP2020516648A (ja) 2017-04-13 2020-06-11 シワ コーポレーション ヒト化モノクローナル終末糖化産物抗体
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
US20210128741A1 (en) 2017-08-23 2021-05-06 Daiichi Sankyo Company, Limited Antibody-drug conjugate preparation and lyophilization for same
CN111051330A (zh) 2017-08-31 2020-04-21 第一三共株式会社 抗体-药物缀合物的改进制备方法
JP7248578B2 (ja) 2017-08-31 2023-03-29 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
CN107789631B (zh) * 2017-11-03 2021-03-16 合肥瀚科迈博生物技术有限公司 抗人ErbB2双表位抗体-药物偶联物及其应用
CA3085432A1 (en) 2017-12-12 2019-06-20 Macrogenics Inc. Bispecific cd16-binding molecules and their use in the treatment of disease
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
BR112020016485A2 (pt) 2018-02-15 2020-12-15 Macrogenics, Inc. Molécula de ligação, composição farmacêutica e método para o tratamento de uma doença
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
US20210205466A1 (en) 2018-05-28 2021-07-08 Daiichi Sankyo Company, Limited Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
IL280301B2 (en) 2018-07-23 2025-06-01 Trevi Therapeutics Inc Treatment of chronic cough, breathlessness and dyspnea
WO2020022363A1 (ja) 2018-07-25 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの効果的な製造方法
JP7406488B2 (ja) 2018-07-27 2023-12-27 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
AU2019315177A1 (en) 2018-07-31 2021-02-25 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
KR20210042120A (ko) 2018-08-06 2021-04-16 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 튜불린 저해제의 조합
US12312641B2 (en) 2018-08-23 2025-05-27 Daiichi Sankyo Company, Limited Sensitivity marker for antibody-drug conjugate
KR20210064325A (ko) 2018-09-25 2021-06-02 에이비에스씨아이, 엘엘씨 단백질 정제 방법
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
SG11202106248XA (en) 2018-12-11 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate with parp inhibitor
JP7624922B2 (ja) 2018-12-19 2025-01-31 インサイト・コーポレイション 胃腸疾患の治療のためのｊａｋ１経路阻害剤
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE AND KINAS INHIBITOR COMBINATION
EP3917963A1 (en) 2019-02-01 2021-12-08 GlaxoSmithKline Intellectual Property Development Limited Belantamab mafodotin in combination with pembrolizumab for treating cancer
JP7589168B2 (ja) 2019-04-01 2024-11-25 ジェネンテック， インコーポレイテッド タンパク質含有製剤を安定化するための組成物および方法
CN112007169B (zh) * 2019-05-30 2022-03-08 湖南大学 一种核酸适配体药物偶联物及其制备方法和用途
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
CN114222760A (zh) 2019-06-26 2022-03-22 葛兰素史密斯克莱知识产权发展有限公司 Il1rap结合蛋白
CN110551214A (zh) * 2019-08-27 2019-12-10 杨澜 一种人源化抗Periostin单克隆抗体、及其制备方法和应用
WO2021142288A1 (en) 2020-01-10 2021-07-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine
WO2021152495A1 (en) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP4106813A4 (en) 2020-02-21 2024-03-27 MacroGenics, Inc. CD137 BINDING MOLECULES AND THEIR USES
CN116615248A (zh) 2020-06-24 2023-08-18 阿斯利康(英国)有限公司 抗体-药物缀合物和cdk9抑制剂的组合
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
KR20230043109A (ko) 2020-06-24 2023-03-30 아스트라제네카 유케이 리미티드 항체-약물 접합체 및 atr 억제제의 조합
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
US20230256110A1 (en) 2020-06-24 2023-08-17 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
WO2022019259A1 (ja) 2020-07-20 2022-01-27 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲートとｈｅｒ二量体化阻害剤の組み合わせ
US20230372527A1 (en) 2020-10-09 2023-11-23 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
CN116916919A (zh) 2020-11-11 2023-10-20 第一三共株式会社 抗体-药物缀合物与抗SIRPα抗体的组合
US20250034274A1 (en) 2021-11-30 2025-01-30 Daiichi Sankyo Company , Limited Protease-cleavable masked antibodies
TW202333800A (zh) 2021-12-28 2023-09-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及rasg12c抑制劑之組合
TW202342106A (zh) 2022-02-09 2023-11-01 日商第一三共股份有限公司 環境應答性遮蔽抗體及其利用
AU2023262308A1 (en) 2022-04-27 2024-10-03 Astrazeneca Uk Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
TW202400650A (zh) 2022-05-11 2024-01-01 日商第一三共股份有限公司 抗體與cd47抑制劑之組合
MA71616A (fr) 2022-07-28 2025-05-30 Daiichi Sankyo Company, Limited Association d'un conjugué anticorps-médicament et d'un inhibiteur de point de contrôle bispécifique
WO2025005240A1 (ja) 2023-06-30 2025-01-02 第一三共株式会社 活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法
WO2025088496A1 (en) 2023-10-24 2025-05-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途
WO2025120513A1 (en) 2023-12-05 2025-06-12 Astrazeneca Uk Limited Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4933294A (en) 1984-01-30 1990-06-12 Icrf Patents Limited Method of detecting truncated epidermal growth factor receptors
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
WO1990014357A1 (en) 1989-05-19 1990-11-29 Genentech, Inc. Her2 extracellular domain
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
EP0494135B1 (en) 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2165851T3 (es) 1991-11-25 2002-04-01 Enzon Inc Proteinas multivalentes que se unen a antigenos.
DE69334351D1 (de) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetisches Bindeprotein für Tumormarker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
EP0655924A4 (en) 1992-06-30 1996-09-11 Oncologix Inc A COMBINATION OF MONOCLONAL ANTIBODIES AGAINST erbB-2 AND METHOD FOR THEIR USE.
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
ES2141128T3 (es) 1993-03-24 2000-03-16 Berlex Biosciences Combinacion de agentes anti-hormonales y moleculas de fijacion.
WO1994022478A1 (en) 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
PT659439E (pt) 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
WO1996016673A1 (en) 1994-12-02 1996-06-06 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5977322A (en) 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
EP2275119B1 (en) 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
JP4382879B2 (ja) * 1996-07-12 2009-12-16 ジェネンテック・インコーポレーテッド ガンマ―ヘレグリン
ATE236872T1 (de) * 1996-08-12 2003-04-15 Celgene Corp Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte
KR20060079258A (ko) * 1996-10-18 2006-07-05 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
EP1187632B1 (en) * 1999-05-14 2008-12-03 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES
EP1191944A2 (en) * 1999-06-25 2002-04-03 Genentech, Inc. METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
EP2112167A3 (en) * 1999-06-25 2010-12-22 Genentech, Inc. Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
KR100754049B1 (ko) * 1999-06-25 2007-08-31 제넨테크, 인크. 전립선암을 치료하기 위한 약제 제조에 사용되는 항-ErbB2 항체 및 조성물
MXPA02002037A (es) * 1999-08-27 2002-10-31 Genentech Inc Dosificaciones para el tratamiento con anticuerpos anti-erb2.

Also Published As

Publication number Publication date
DE10084743T1 (de) 2002-08-14
CA2376596C (en) 2009-10-06
NO20016329L (no) 2002-02-25
NO328377B1 (no) 2010-02-08
DK1189641T3 (da) 2009-11-16
JP2009142280A (ja) 2009-07-02
BR122014028365B1 (pt) 2020-01-28
AR024464A1 (es) 2002-10-02
CZ20014596A3 (cs) 2003-02-12
AU2005242195A1 (en) 2006-01-12
NZ516830A (en) 2004-07-30
DK1189641T5 (da) 2011-04-11
CN101121021B (zh) 2011-12-07
NO336040B1 (no) 2015-04-27
NO20091792L (no) 2002-02-25
CN101518653B (zh) 2015-08-19
CH694589A5 (de) 2005-04-15
BR0012198A (pt) 2002-04-02
CA2376596A1 (en) 2001-01-04
RU2270029C2 (ru) 2006-02-20
WO2001000245A2 (en) 2001-01-04
JP2003503366A (ja) 2003-01-28
CY2013010I1 (el) 2015-08-05
NO2013005I1 (no) 2013-04-02
RU2005132788A (ru) 2007-04-27
IL197359A0 (en) 2011-07-31
BRPI0012198B1 (pt) 2016-12-20
PT1189641E (pt) 2009-11-04
KR20070094993A (ko) 2007-09-27
LU92164I2 (fr) 2013-05-07
WO2001000245A3 (en) 2001-10-25
ZA200110263B (en) 2003-02-26
GEP20104998B (en) 2010-06-10
NZ531426A (en) 2005-10-28
HK1044888A1 (en) 2002-11-08
AU2005242195B2 (en) 2009-06-11
GB2368796A (en) 2002-05-15
SI1189641T1 (sl) 2009-12-31
MXPA01013458A (es) 2002-07-30
AU5763200A (en) 2001-01-31
CN101121750A (zh) 2008-02-13
CN1370082A (zh) 2002-09-18
DE60042648D1 (de) 2009-09-10
HUP0201695A2 (en) 2002-09-28
SI2283867T1 (sl) 2014-07-31
EP2112167A3 (en) 2010-12-22
NO20016329D0 (no) 2001-12-21
ATE437655T1 (de) 2009-08-15
CY2013010I2 (el) 2015-08-05
GB0200506D0 (en) 2002-02-27
EP2112167A2 (en) 2009-10-28
CY1109525T1 (el) 2014-08-13
ES2329437T3 (es) 2009-11-26
CN100340575C (zh) 2007-10-03
KR100797308B1 (ko) 2008-01-23
BE2013C020I2 (enExample) 2019-08-21
EP1189641A2 (en) 2002-03-27
CN101121021A (zh) 2008-02-13
AT500848A1 (de) 2006-04-15
KR100850389B1 (ko) 2008-08-04
CZ299702B6 (cs) 2008-10-22
GB2368796B (en) 2004-08-04
KR20020068264A (ko) 2002-08-27
RU2430739C9 (ru) 2015-12-20
AT500848B1 (de) 2008-01-15
IL146954A0 (en) 2002-08-14
HU226742B1 (en) 2009-08-28
BR122014028365B8 (pt) 2021-07-06
RU2430739C2 (ru) 2011-10-10
PL204629B1 (pl) 2010-01-29
BRPI0012198B8 (pt) 2021-05-25
EP1189641B1 (en) 2009-07-29
SI2283866T1 (sl) 2015-07-31
FR13C0016I1 (enExample) 2013-04-12
PL352321A1 (en) 2003-08-11
IL146954A (en) 2009-09-22
CN101518653A (zh) 2009-09-02
CA2727172A1 (en) 2001-01-04
TR200103756T2 (tr) 2002-06-21
HUP0201695A3 (en) 2005-06-28
PL203326B1 (pl) 2009-09-30
AU784045B2 (en) 2006-01-19
ZA200109786B (en) 2002-11-28
NO2013005I2 (no) 2013-03-12
FR13C0016I2 (fr) 2014-05-16

Similar Documents

Publication Publication Date Title
JP4283474B2 (ja) ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療
JP4969440B2 (ja) 疼痛治療のためのＥｒｂＢアンタゴニスト
US6949245B1 (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20070184055A1 (en) Treatment with anti-erbb2 antibodies
US20040013667A1 (en) Treatment with anti-ErbB2 antibodies
JP2003503361A (ja) 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
JP2006516117A (ja) 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
HK1044888B (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
HK1130502A (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080415

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20080724

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20080825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090317

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090319

R150 Certificate of patent or registration of utility model

Ref document number: 4283474

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120327

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120327

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130327

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130327

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140327

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term